Mark Elliott Boulding
Net Worth

Last updated:

What is Mark Elliott Boulding net worth?

The estimated net worth of Mr. Mark Elliott Boulding is at least $23,315,558 as of 3 Dec 2024. He owns shares worth $4,537,224 as insider, has earned $9,930,484 from insider trading and has received compensation worth at least $8,847,850 in PTC Therapeutics, Inc..

What is the salary of Mark Elliott Boulding?

Mr. Mark Elliott Boulding salary is $804,350 per year as Executive Vice President & Chief Legal Officer in PTC Therapeutics, Inc..

How old is Mark Elliott Boulding?

Mr. Mark Elliott Boulding is 64 years old, born in 1961.

What stocks does Mark Elliott Boulding currently own?

As insider, Mr. Mark Elliott Boulding owns shares in one company:

Company Title Shares Price per share Total value
PTC Therapeutics, Inc. (PTCT) Executive Vice President & Chief Legal Officer 92,389 $49.11 $4,537,224

What does PTC Therapeutics, Inc. do?

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

PTCT logo
PTCT
PTC Therapeutics, Inc.
$49.11

Mark Elliott Boulding insider trading

PTC Therapeutics, Inc.

Mr. Mark Elliott Boulding has made 32 insider trades between 2014-2024, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 104,092 units of PTCT stock on 1 Jul 2019. As of 3 Dec 2024 he still owns at least 92,389 units of PTCT stock.

Transaction Date Security Shares Price per share Total value Source
Option
Stock Option (Right to Buy) 7,720 $33.02 $254,914
Option
Stock Option (Right to Buy) 1,988 $33.02 $65,644
Option
Common Stock 1,988 $33.02 $65,644
Option
Common Stock 7,720 $33.02 $254,914
Sale
Common Stock 6,315 $53.14 $335,579
Sale
Common Stock 2,093 $53.74 $112,484
Sale
Common Stock 1,900 $53.13 $100,947
Option
Stock Option (Right to Buy) 600 $33.02 $19,812
Option
Common Stock 600 $33.02 $19,812
Option
Stock Option (Right to Buy) 83,640 $51 $4,265,640
Option
Stock Option (Right to Buy) 1,960 $51 $99,960
Sale
Common Stock 85,600 $52.22 $4,469,604
Option
Common Stock 1,960 $51 $99,960
Option
Common Stock 83,640 $51 $4,265,640
Sale
Common Stock 794 $27.25 $21,637
Sale
Common Stock 1,938 $29.02 $56,231
Sale
Common Stock 1,457 $28.64 $41,728
Option
Stock Option (Right to Buy) 58,631 $30.86 $1,809,353
Option
Common Stock 3,292 $30.86 $101,591
Option
Common Stock 58,631 $30.86 $1,809,353
Option
Stock Option (Right to Buy) 3,292 $30.86 $101,591
Sale
Common Stock 61,923 $51.42 $3,183,957
Sale
Common Stock 812 $45.63 $37,050
Sale
Common Stock 495 $44.36 $21,958
Sale
Common Stock 590 $42.93 $25,330
Sale
Common Stock 835 $41.66 $34,783
Option
Stock Option (Right to Buy) 289 $30.86 $8,919
Sale
Common Stock 289 $55.04 $15,907
Option
Stock Option (Right to Buy) 10 $30.86 $309
Option
Common Stock 10 $30.86 $309
Option
Common Stock 289 $30.86 $8,919
Sale
Common Stock 6,402 $55 $352,110
Option
Stock Option (Right to Buy) 200 $30.86 $6,172
Option
Common Stock 6,402 $30.86 $197,566
Option
Stock Option (Right to Buy) 6,402 $30.86 $197,566
Option
Common Stock 200 $30.86 $6,172
Option
Stock Option (Right to Buy) 876 $30.86 $27,033
Option
Common Stock 300 $30.86 $9,258
Option
Common Stock 876 $30.86 $27,033
Option
Stock Option (Right to Buy) 300 $30.86 $9,258
Sale
Common Stock 300 $55 $16,500
Option
Stock Option (Right to Buy) 2,276 $11.23 $25,559
Sale
Common Stock 2,276 $45.17 $102,811
Option
Common Stock 2,276 $11.23 $25,559
Sale
Common Stock 5 $45 $225
Option
Common Stock 5 $11.23 $56
Option
Stock Option (Right to Buy) 5 $11.23 $56
Option
Common Stock 2,282 $11.23 $25,627
Option
Stock Option (Right to Buy) 2,282 $11.23 $25,627
Option
Common Stock 15,653 $18.01 $281,911
Option
Stock Option (Right to Buy) 15,653 $18.01 $281,911
Sale
Common Stock 15,653 $45.03 $704,808
Sale
Common Stock 779 $40 $31,162
Sale
Common Stock 885 $38.53 $34,095
Option
Common Stock 3,363 $18.01 $60,568
Sale
Common Stock 3,363 $45.01 $151,375
Option
Stock Option (Right to Buy) 3,363 $18.01 $60,568
Option
Stock Option (Right to Buy) 1,429 $45 $64,306
Option
Common Stock 1,429 $45 $64,306
Sale
Common Stock 548 $45 $24,660
Option
Common Stock 6,805 $38.42 $261,434
Sale
Common Stock 1,000 $11.23 $11,230
Option
Stock Option (Right to Buy) 5,705 $36.72 $209,488
Option
Stock Option (Right To Buy) 2,100 $28.22 $59,264
Sale
Common Stock 778 $56.96 $44,312
Sale
Common Stock 772 N/A N/A
Option
Stock Option (Right To Buy) 30,625 $14.62 $447,738
Sale
Common Stock 30,525 N/A N/A
Option
Common Stock 30,625 N/A N/A
Option
Common Stock 30,625 $14.62 $447,738
Option
Stock Option (Right To Buy) 30,625 N/A N/A
Option
Stock Option (Right To Buy) 15,312 N/A N/A
Sale
Common Stock 11,374 N/A N/A
Option
Common Stock 7,656 N/A N/A
Sale
Common Stock 5,910 N/A N/A
Option
Common Stock 104,092 N/A N/A
Option
Stock Option (Right To Buy) 32,859 N/A N/A
Option
Common Stock 77,575 N/A N/A
Option
Stock Option (Right To Buy) 77,575 N/A N/A
Sale
Common Stock 7,533 N/A N/A
Option
Stock Option (Right to Buy) 62,083 N/A N/A
Option
Common Stock 62,083 N/A N/A
Sale
Common Stock 56,849 N/A N/A
Sale
Common Stock 21,142 N/A N/A
Sale
Common Stock 10,049 N/A N/A

PTC Therapeutics key executives

PTC Therapeutics, Inc. executives and other stock owners filed with the SEC: